natgillin/translations-raw huggingface dataset:
Actos must not be used in patients who have problems with their liver, patients who have had heart failure (when the heart does not work as well as it should) or patients with diabetic ketoacidosis (a complication of diabetes).
Zdravila ne smejo uporabljati bolniki, ki imajo težave z jetri, bolniki s srčnim popuščanjem (pri katerih srce ne deluje, kot bi moralo) ali bolniki z diabetično ketoacidozo (zapletom pri sladkorni bolezni).
The active substance in Actos, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Zdravilna učinkovina zdravila Actos, pioglitazon, poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo bolje izrablja insulin, ki ga proizvaja.
What is the risk associated with Actos?
Kakšna tveganja so povezana z zdravilom Actos?
Actos led to a decrease in the level of HbA1c, indicating that blood glucose levels had been reduced at doses of 15, 30 and 45 mg. Actos on its own was shown to be as effective as metformin and gliclazide.
Zdravilo Actos je znižalo ravni HbA1c, kar pomeni, da se je raven glukoze v krvi znižala pri odmerkih 15 mg, 30 mg in 45 mg. Kot samostojno zdravilo se je izkazalo za enako učinkovito kot metformin in gliklazid.
Why has Actos been approved?
Zakaj je bilo zdravilo Actos odobreno?
The studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
V študijah so merili raven snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako dobro je raven glukoze v krvi uravnavana.
This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed.
Priporočeni začetni odmerek zdravila Actos je 15 ali 30 mg enkrat na dan. Odmerek bo po enem ali dveh tednih morda treba povečati na 45 mg enkrat na dan, če je potrebno boljše uravnavanje glukoze (sladkorja) v krvi.
Some studies also looked at combining Actos with a sulphonylurea, insulin or metformin, or with the combination of metformin and a sulphonylurea.
V nekaterih študijah so proučevali tudi kombiniranje zdravila Actos s sulfonilsečnino, insulinom ali metforminom ali s kombinacijo metformina in sulfonilsečnine.
Actos also improved the glucose control obtained in type 2 diabetes when it was added to existing treatment with a sulphonylurea, insulin or metformin, or the combination of metformin and a sulphonylurea.
Z zdravilom Actos je bila tudi bolje nadzorovana glukoza pri sladkorni bolezni tipa 2, če se je dodalo obstoječemu zdravljenju s sulfonilsečnino, insulinom ali metforminom ali kombinaciji metformina in sulfonilsečnine.
• on its own in patients for whom metformin (another diabetes medicine) is not suitable;
• kot samostojno zdravilo pri bolnikih, za katere metformin (drugo zdravilo za zdravljenje sladkorne bolezni) ni primerno;
For the full list of all side effects reported with Actos, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Actos, glejte navodilo za uporabo.
• together with insulin in patients who are not satisfactorily controlled with insulin alone and cannot take metformin.
• skupaj z insulinom pri bolnikih, pri katerih bolezen ni zadostno nadzorovana zgolj z insulinom in za katere metformin ni primeren.
• in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of diabetes medicine) when metformin is not suitable in patients who are not satisfactorily controlled on a sulphonylurea alone;
• v kombinaciji z metforminom pri bolnikih, pri katerih zgolj z metforminom ni mogoče doseči zadovoljivega uravnavanj, ali s sulfonilsečnino (drugo vrsto zdravila za zdravljenje sladkorne bolezni), če metformin ni primeren, pri bolnikih, pri katerih zgolj s sulfonilsečnino ni mogoče doseči zadovoljivega uravnavanja;
How has Actos been studied?
Kako je bilo zdravilo Actos raziskano?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Actos have also been included in the summary of product characteristics and the package leaflet.
V povzetek glavnih značilnosti zdravila in navodilo za uporabo so bili vključeni priporočila in previdnostni ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki za varno in učinkovito uporabo zdravila Actos.
Actos has been compared with placebo (a dummy treatment), metformin and gliclazide (a sulphonylurea) in a number of studies.
Zdravilo Actos so v številnih študijah primerjali s placebom (zdravilom brez zdravilne učinkovine), metforminom in gliklazidom (sulfonilsečnino).
How does Actos work?
Kako zdravilo Actos deluje?
What is Actos used for?
Za kaj se zdravilo Actos uporablja?
How is Actos used?
Kako se zdravilo Actos uporablja?
What is Actos?
Kaj je zdravilo Actos?
are continuously monitored.
stalno spremljajo.
and why it is authorised in the EU
in zakaj je odobreno v EU
authorised in the EU?
odobreno v EU?
The recommended dose is one tablet once a day, preferably taken with food.
Priporočeni odmerek je ena tableta na dan, ki se po možnosti vzame s hrano.
In addition, it may be used in adolescents who are resistant to first-line treatments or who cannot take them because of side effects.
Poleg tega se lahko uporablja tudi pri mladostnikih, ki so odporni proti zdravilom prve izbire ali teh zaradi neželenih učinkov ne morejo jemati.
is available as tablets (200 mg emtricitabine and 245 mg tenofovir disoproxil).
je na voljo v obliki tablet (200 mg emtricitabina in 245 mg dizoproksiltenofovirata).
Two medicines are bioequivalent when they produce the same levels of the active substances in the body and are therefore expected to have the same effect.
Dve zdravili sta biološko enakovredni, kadar dosegata enake ravni učinkovine v telesu in imata zato po pričakovanjih enak učinek.
is an HIV medicine that is used in combination with at least one other HIV medicine to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
je zdravilo proti virusu HIV, ki se uporablja v kombinaciji z vsaj enim drugim tovrstnim zdravilom za zdravljenje odraslih, okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
does not cure HIV infection or AIDS, but it holds off the damage to the immune system and the development of infections and diseases associated with AIDS.
ne zdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter razvoj okužb in bolezni, povezanih z aidsom.
can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection.
je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
(emtricitabine / tenofovir disoproxil)
(emtricitabin/dizoproksiltenofovirat)
The company also carried out a study that showed that it is ‘bioequivalent' to the reference medicine.
Izvedla je tudi študijo, ki je pokazala, da je zdravilo biološko enakovredno referenčnemu zdravilu.
If patients need to stop taking emtricitabine or tenofovir, or need to take different doses, they will need to take medicines containing emtricitabine or tenofovir disoproxil separately.
Če bi morali bolniki prekiniti jemanje emtricitabina ali tenofovirja oziroma bi bilo treba njune odmerke spremeniti, morajo preiti na zdravila, ki ločeno vsebujejo emtricitabin ali dizoproksiltenofovirat.
Studies on the benefits and risks of the active substances in the authorised use have already been carried out with the reference medicine, Truvada, and do not need to be repeated for Emtricitabine/Tenofovir disoproxil Krka d.d.
Študije o koristih in tveganjih obeh učinkovin pri odobrenem načinu uporabe so že bile izvedene z referenčnim zdravilom Truvada, zato jih ni treba ponoviti za zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
contains two active substances: emtricitabine, which is a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil, which is a ‘prodrug' of tenofovir.
vsebuje dve učinkovini: emtricitabin, ki je nukleozidni zaviralec reverzne transkriptaze, in dizoproksiltenofovirat, ki je „predzdravilo“ tenofovirja.
Side effects reported with Emtricitabine/Tenofovir disoproxil Krka are carefully evaluated and any necessary action taken to protect patients.
Emtricitabin/dizoproksiltenofovirat Krka d.d, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
The European Medicines Agency concluded that, in accordance with EU requirements, Emtricitabine/Tenofovir disoproxil Krka d.d.
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
For more informationabout using Emtricitabine/Tenofovir disoproxil Krka d.d., see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
can be found on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/emtricitabinetenofovir-disoproxil-krka-dd. Information on the reference medicine can also be found on the Agency's website.
Nadaljnje informacije o zdravilu Emtricitabin/dizoproksiltenofovirat Krka d.d so na voljo na spletni strani agencije: ema.europa.eu/en/medicines/human/EPAR/emtricitabinetenofovir-disoproxil-krka-dd.
What measures are being taken to ensure the safe and effective use of Emtricitabine/Tenofovir disoproxil Krka d.d.
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d.
As for every medicine, the company provided studies on the quality of Emtricitabine/Tenofovir disoproxil Krka d.d.
Tako kot za vsako zdravilo, je družba predložila študije o kakovosti zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d.
Emtricitabine/Tenofovir disoproxil Krka d.d., taken in combination with at least one other antiviral medicine, reduces the amount of HIV in the blood and keeps it at a low level.
v kombinaciji z vsaj enim zdravilom proti okužbi z virusom HIV zniža količino virusa HIV v krvi in jo zadržuje na nizki ravni.
What are the benefits and risks of Emtricitabine/Tenofovir disoproxil Krka d.d.
Kakšne so koristi in tveganja, povezani z zdravilom Emtricitabin/dizoproksiltenofovirat Krka d.d.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Emtricitabine/Tenofovir disoproxil Krka d.d.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d.
has been shown to have comparable quality and to be bioequivalent to Truvada.
primerljivo raven kakovosti kot referenčno zdravilo Truvada ter da mu je biološko enakovredno.
have also been included in the summary of product characteristics and the package leaflet.
upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
As for all medicines, data on the use of Emtricitabine/Tenofovir disoproxil Krka d.d.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d.
Other information about Emtricitabine/Tenofovir disoproxil Krka d.d.
Druge informacije o zdravilu Emtricitabin/dizoproksiltenofovirat Krka d.d.
will provide an information pack to doctors which covers the potential harmful effects of Emtricitabine/Tenofovir disoproxil Krka d.d.
Družba, ki trži zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d., bo pripravila informativno gradivo za zdravnike, ki bo obsegalo opis možnih škodljivih učinkov tega zdravila na delovanje ledvic pri odraslih in otrocih.
The European Commission granted a marketing authorisation valid throughout the EU for Emtricitabine/Tenofovir disoproxil Krka d.d.
Evropska komisija je dovoljenje za promet z zdravilom Emtricitabin/dizoproksiltenofovirat Krka d.d., veljavno po vsej EU, izdala 28. aprila 2017.
Why is Emtricitabine/Tenofovir disoproxil Krka d.d.
Zakaj je bilo zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
Because Emtricitabine/Tenofovir disoproxil Krka d.d.
Ker je zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
Emtricitabine/Tenofovir disoproxil Krka d.d contains two active substances, emtricitabine and tenofovir disoproxil.
vsebuje dve učinkovini, emtricitabin in dizoproksiltenofovirat.
An overview of Emtricitabine/Tenofovir disoproxil Krka d.d.
Pregled zdravila Emtricitabin/dizoproksiltenofovirat Krka d.d.
What is Emtricitabine/Tenofovir disoproxil Krka d.d.
Kaj je zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
Emtricitabine/Tenofovir disoproxil Krka d.d.
Zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
How is Emtricitabine/Tenofovir disoproxil Krka d.d.
Kako je bilo zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
How has Emtricitabine/Tenofovir disoproxil Krka d.d.
Kako se zdravilo Emtricitabin/dizoproksiltenofovirat Krka d.d.
The procedure started on 19 July 2007.
Postopek se je začel dne 19. julija 2007.
Ref. EMEA/CHMP/384874/2008
EMEA/CHMP/554251/2008
A Decision was issued by the European Commission on 7 October 2008.
Odločbo je Evropska komisija izdala 7. oktobra 2008.
London, 7 October 2008 Doc.
London, 7. oktober 2008 Sklic na dok.
The Marketing Authorisation Holder provided supplementary information on 23 November 2007 and 22 April 2008.
Imetnik dovoljenja za promet je dne 23. novembra 2007 in 22. aprila 2008 priskrbel dodatne informacije.
It is available as immediate release film coated tablets, modified release film coated tablets, granules and solutions for oral suspension, solutions for infusion in bags, solutions for infusion in bottles and sachets.
Na voljo je v obliki filmsko obloženih tablet s takojšnjim sproščanjem, filmsko obloženih tablet s prirejenim sproščanjem, zrnc in raztopin za peroralno suspenzijo, raztopin za infundiranje v vrečkah ter raztopin za infundiranje v stekleničkah in vrečkah.
Ciprofloxacin Bayer and associated names is an antibiotic, indicated for the treatment of uncomplicated and complicated infections, including severe infections, caused by ciprofloxacin susceptible pathogens.
Zdravilo Ciprofloxacin Bayer in povezana imena je antibiotik, namenjen zdravljenju nezapletenih in zapletenih okužb, vključno hudih okužb, ki jih povzročajo na ciprofloksacin občutljivi patogeni.
On 22 June 2007, France presented to the EMEA a referral under Article 30 of Directive 2001/83/EC, as amended, in order to harmonise the nationally authorised Summaries of Product Characteristics (SPC), Labelling and Package Leaflet of the medicinal product Ciprofloxacin Bayer and associated names.
Francija je dne 22. junija 2007 agenciji EMEA predložila napotitev v skladu s členom 30 Direktive 2001/83/ES, kakor je bila spremenjena, za uskladitev na nacionalni ravni odobrenih povzetkov glavnih značilnosti zdravila (SPC), označevanj in navodil za uporabo zdravila Cyprofloxacin Bayer in povezanih imen.
The basis for referral was that there were divergences in the Summaries of Product Characteristics (SPC) of Ciprofloxacin Bayer and associated names approved across EU Member States, with respect to the indications, the posology, the contra-indications and the special warnings and precautions for use.
Podlaga za napotitev so bila razhajanja med povzetki glavnih značilnosti zdravila (SPC) Ciprofloxacin Bayer in povezanih imen, ki so bili odobreni v državah članicah EU, zlasti v zvezi z indikacijami, odmerjanjem, kontraindikacijami ter posebnimi opozorili in previdnostnimi ukrepi.
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 30 REFERRAL FOR Ciprofloxacin Bayer and associated names International Non-Proprietary Name (INN): ciprofloxacin
ODBOR ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI (CHMP) MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 30 ZA zdravilo Ciprofloxacin Bayer in povezana imena Mednarodno nelastniško ime (INN): ciprofloksacin
During its July 2008 meeting, the CHMP, in the light of the overall submitted data and the scientific discussion within the Committee, was of the opinion that the proposal for the harmonisation of the SPC, Labelling and Package Leaflet was acceptable and that they should be amended.
Med svojim zasedanjem julija 2008 je CHMP na osnovi vseh predloženih podatkov in znanstvene razprave v Odboru menil, da je predlog za uskladitev povzetkov glavnih značilnosti zdravila, označevanj in navodil za uporabo sprejemljiv in da bi bilo treba navedene dokumente dopolniti.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amended SPC, Labelling and Package Leaflet in Annex III.
Seznam zadevnih imen zdravil je naveden v Dodatku I. Znanstveni zaključki so na voljo v Dodatku II, dopolnjeni povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo pa v Dodatku III.
The CHMP gave a positive opinion on 24 July 2008 recommending the harmonisation of the SPC, Labelling and Package Leaflet for Ciprofloxacin Bayer and associated names.
CHMP je dne 24. julija 2008 izdal pozitivno mnenje, s katerim priporoča uskladitev povzetkov glavnih značilnosti zdravila, označevanj in navodil za uporabo za zdravilo Ciprofloxacin Bayer in povezana imena.
This medicinal product belongs to the list of products identified in 2007 for SPC harmonisation.
Zdravilo spada na seznam zdravil iz leta 2007, katerih povzetke glavnih značilnosti zdravila je treba uskladiti.
In the MRP Sweden is the Reference Member State and Austria, Belgium, Finland, France, Germany, Italy, Ireland, Luxembourg, Portugal, Spain and the United Kingdom are the Concerned Member States.
V postopku medsebojnega priznavanja je bila Švedska referenčna država članica, medtem ko so bile Avstrija, Belgija, Finska, Francija, Nemčija Italija, Irska, Luksemburg, Portugalska, Španija in Združeno kraljestvo zadevne države članice.
The doctor will assess whether you can take Viani during this time.
Zdravnik bo ocenil, ali lahko v tem obdobju uporabljate Viani.
- When you close the Diskus, it clicks shut.
- Ko se Diskus zapre, klikne.
When you first take Viani Diskus out of the box, it will be in the closed position.
Ko Viani Diskus prvič vzamete iz škatle, je v zaprtem položaju.
B-1332 Genval, Belgium
B-1332 Genval, Belgija
WHAT VIANI IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO VIANI IN ZA KAJ GA UPORABLJAMO
Estrada Marco do Grilo Zemouto, 2830 Coina Portugal
Estrada Marco do Grilo Zemouto, 2830 Coina Portugalska
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF VIANI DISKUS AND ASSOCIATED NAMES (SEE ANNEX I)
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA VIANI DISKUS IN Z NJIM POVEZANIH IMEN (GLEJTE DODATEK I)
Each single dose of Viani provides:
En posamični odmerek zdravila Viani vsebuje:
Do not stop taking Viani suddenly as this could make your symptoms worse and could cause problems with the body's hormones.
Zdravila Viani ne nehajte jemati nenadoma, ker to lahko poslabša simptome in povzroči težave s hormoni v telesu.
• the CHMP considered the referral made under Article 6(13) of Commission Regulation (EC) N 1084/2003 for Viani Diskus and associated names (see Annex I)
• CHMP je upošteval napotitev v skladu s členom 6(13) Uredbe Komisije (ES) št. 1084/2003 za zdravilo Viani Diskus in z njim povezana imena (glejte Dodatek I).
Do not use Viani after the expiry date which is stated on the label and carton.
Zdravila Viani ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli.
In several EU Member States Viani Diskus and associated names (see Annex I) are approved through the Mutual Recognition Procedure (MRP).
V več državah članicah EU je bilo zdravilo Viani Diskus in z njim povezana imena (glejte Dodatek I) odobreno s postopkom medsebojnega priznavanja.
In some cases, Viani may not be suitable to be taken with other medicines.
Včasih zdravila Viani ni primerno jemati z drugimi zdravili.
Allen Pharmazeutika Pharma GmbH, Albert-Schweitzer-Gasse 6 A-1140 Wien
Allen Pharmazeutika Pharma GmbH, Albert-Schweitzer-Gasse 6, A-1140 Wien, Avstrija
If your symptoms are well controlled using Viani Diskus twice daily, your doctor may decide to reduce your dose to once daily.
Če so simptomi dobro obvladani z uporabo Viani Diskusa dvakrat na dan, se bo zdravnik morda odločil za zmanjšanje odmerka na enkrat na dan.
If you notice these symptoms or they appear suddenly after taking Viani, tell your doctor immediately as you could be allergic to Viani.
Če opazite te simptome ali če se pojavijo nenadoma po uporabi zdravila Viani, morate to takoj povedati zdravniku, kajti morda ste alergični na Viani.
- Viani may affect the normal production of steroid hormones in the body, particularly if you have taken high doses for long periods of time.
- Viani lahko neugodno vpliva na normalno nastajanje steroidnih hormonov v telesu, zlasti če dolgo časa uporabljate velike odmerke.
Viani Diskus is also used for the regular treatment of the symptoms of severe Chronic Obstructive Pulmonary Disease (COPD).
Viani Diskus uporabljamo tudi za redno zdravljenje simptomov hude kronične pljučne obstruktivne bolezni (KOPB).
GlaxoSmithKline AB Box 516, SE-169 29 Solna Sweden
GlaxoSmithKline AB Box 516, SE-169 29 Solna Švedska
If you stop taking Viani
Če nehate jemati Viani
Viani is indicated for the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Viani je indiciran za simptomatsko zdravljenje bolnikov s hudo KOPB (FEV1 < 50 % predvidenega normalnega) in anamnezo ponavljajočih se poslabšanj, ki imajo izrazite simptome kljub redni bronhodilatacijski terapiji.
Viani contains salmeterol and fluticasone propionate which have differing modes of action.
Viani vsebuje salmeterol in flutikazonijev propionat, ki imata različen mehanizem delovanja.
Tell your doctor, but do not stop taking Viani unless they tell you to do so.
Povedati morate zdravniku, vendar ne nehajte uporabljati zdravila Viani, dokler vam ne naroči tako.
To work properly in controlling asthma and treating COPD symptoms, Viani must be taken every day as directed by your doctor.
Za ustrezno obvladanje astme in zdravljenje simptomov KOPB morate Viani jemati vsak dan, kot vam je predpisal zdravnik.
If your asthma gets worse or is not well controlled (you will feel wheezy and need more of your fast acting ‘rescue' medicine), do not increase the number of inhalations of Viani you take.
Če se vam astma poslabša ali ni dobro obvladana (kar pomeni, da ste pogosteje zasopli in morate pogosteje uporabljati hitrodelujoče "olajševalno" zdravilo), ne povečujte števila vdihov zdravila Viani.
Patients should be regularly reassessed by a doctor, so that the strength of Viani they are receiving remains optimal and is only changed on medical advice.
Bolnike mora zdravnik redno kontrolirati, da ostane uporabljana jakost zdravila Viani optimalna in se spremeni le na zdravniški nasvet.
Note: Viani 50/100 microgram strength is not appropriate in adults and children with severe asthma.
Opomba: Viani v jakosti 50/100 mikrogramov ni primeren za odrasle in otroke s hudo astmo.
Be careful not to confuse your Viani inhaler with your ‘rescue' inhaler.
Pazite, da ne boste inhalatorja Viani zamenjali z inhalatorjem "olajševalnega" zdravila.
It is very important that you take your Viani every day as directed, until you are advised to stop by your doctor.
Zelo pomembno je, da Viani uporabljate vsak dan in po navodilih, dokler vam zdravnik ne svetuje, da nehate.
The doctor will prescribe the lowest strength of Viani Diskus that will best control your symptoms.
Zdravnik vam bo predpisal tisto najmanjšo jakost zdravila Viani Diskus, ki bo najbolje obvladala simptome.